PD-1

[Nature Cancer] Researchers systematically characterized the interactions between T cells and antigen-presenting myeloid cells within the tumor microenvironment and found that CD4+PD-1+CXCL13+ T cells were a major interacting hub with antigen-presenting cells in the tumor microenvironment of human non-small cell lung carcinoma.

[CatalYm] CatalYm today announced treatment of the first patients in a series of Phase IIa cohorts targeting solid tumors, initiating Phase II development of CTL-002, a monoclonal antibody against the novel cancer target growth and differentiation Factor 15.

[Akeso, Inc. (BioSpace, Inc.)] -Akeso, Inc. announced that it entered into a collaboration agreement with Shenzhen Chipscreen Biosciences Co., Ltd. to establish a clinical trial partnership to jointly conduct a Phase Ib/II clinical trial of PD-1/CTLA-4 bi-specific antibody Cadonilimab in combination with Chiauranib for the treatment of first-line platinum-based chemotherapy in combination with PD-(L)1 inhibitor treatment regimen for extensive stage small cell lung cancer.

[Bone Marrow Transplantation] Scientists investigated whether gilteritinib, a selective FLT3 inhibitor, could enhance graft-versus-leukemia effects against FLT3 internal tandem duplication mutant transfected Ba/F3 leukemia in mice.

[Scientific Reports] Mechanistic insights demonstrated that blockade of the PD-1 axis decreased stem-like marker ALDH and expression of DNA repair genes.

[Scientific Reports] Researchers generated thymus-complemented chimeric mice, assessed the efficacy of anti-PD-L1 antibody in tumor-bearing chimeric mice, and then investigated T cell function.